Saw Palmetto vs Stinging Nettle Root for BPH — separate or combined?
Saw palmetto is the most-studied phytotherapy for benign prostatic hyperplasia; the standardised lipid extract has decades of European trial data and is licensed as a drug for BPH in Germany. Stinging nettle root has a much smaller monograph as a standalone but appears in many of the same European fixed-dose combinations alongside saw palmetto, where the combination has the best trial data. Neither supplement reverses prostate enlargement — both target the urinary-symptom (IPSS) endpoint.
Quick verdict
| Scenario | Better choice | Why |
|---|---|---|
| Mild-moderate BPH symptoms (IPSS 8–19) | Saw palmetto (standardised lipid extract) or the combination | The standardised extract Permixon has the largest trial weight; combinations with nettle perform similarly. |
| Nocturia-dominant LUTS | Combination (saw palmetto + nettle) | The Permixon-style fixed-dose combinations have data here. |
| Severe symptoms (IPSS >19) or retention | Neither — urology referral | Alpha-blockers, 5-ARIs, or surgery are first-line. |
| Allergy / hay-fever symptoms with BPH | Stinging nettle (added value) | Nettle's antihistamine signal is for allergic-rhinitis-style symptoms; an adjacency, not a BPH benefit. |
| Concern about ED / ejaculatory dysfunction | Saw palmetto | Lower rate of sexual side effects than tamsulosin or finasteride. |
| Prostate-cancer surveillance | Neither replaces standard workup | Saw palmetto does not lower PSA; nettle does not affect PSA. |
How they actually differ
Mechanism — lipidosterolic extract vs lignan-rich root
Saw palmetto's standardised lipid extract (Serenoa repens / Permixon, Sabal extract) contains free fatty acids, sterols, and aliphatic alcohols. Proposed mechanisms include modest inhibition of 5-alpha-reductase (smaller magnitude than finasteride), anti-inflammatory effects in prostatic tissue, and possible alpha-1-adrenergic modulation. The biological footprint is broader and less reductase-driven than finasteride — which may explain the smaller PSA effect and fewer sexual side effects.
Stinging nettle root contains lignans (secoisolariciresinol, isolariciresinol), polysaccharides, and lectins. Proposed BPH mechanisms include binding of sex hormone-binding globulin (potentially reducing free testosterone delivery to the prostate), inhibition of prostatic aromatase, and anti-inflammatory effects in prostatic tissue. The mechanism rationale is plausible; the monotherapy trial weight is thinner.
Evidence base by endpoint
- Saw palmetto monotherapy: The Cochrane 2012 update (Tacklind, 32 RCTs, 5666 men) found saw palmetto did not significantly improve LUTS vs placebo at standard doses (320 mg/day) using rigorous trial criteria. Effect was smaller than tamsulosin and finasteride. However, several European trials of the Permixon-grade extract (PRACTIS, PERMAL trials) have shown non-inferiority to tamsulosin on IPSS and bother scores — the extract quality matters substantially.
- Stinging nettle monotherapy: Safarinejad 2005 RCT (620 men, 6 months) found nettle 120 mg b.i.d. improved IPSS by ~5 points vs ~1 point placebo. Smaller trials show similar signal direction. Trial weight is thinner than saw palmetto.
- Combination (saw palmetto + nettle): Several German trials of the fixed-dose combination (Sabal + Urtica, e.g. PRO 160/120) have shown LUTS improvement comparable to tamsulosin and finasteride at 24+ weeks. Cleanest combination evidence in the phytotherapy space.
- Effect on prostate volume: Modest in long-term combination trials; not equivalent to 5-ARIs in volume reduction.
- Effect on PSA: Saw palmetto does not consistently lower PSA — important for prostate-cancer surveillance interpretation (unlike finasteride, which approximately halves PSA).
Dose and form
Saw palmetto: 320 mg/day standardised lipid extract (85–95% fatty acids and sterols), either as a single dose or 160 mg b.i.d. Permixon is the most-studied branded extract. Cheaper "dried berry powder" capsules are not interchangeable with the lipid extract.
Stinging nettle root: 120 mg b.i.d. (Safarinejad trial dose) or 240–600 mg/day equivalent of a methanolic or aqueous extract. Standardisation is much less consistent across brands than for saw palmetto.
Combination: 160 mg saw palmetto + 120 mg nettle root b.i.d. is the most-studied fixed-dose combination.
Safety
Saw palmetto is generally well-tolerated. Lower rates of sexual side effects than tamsulosin or finasteride is a frequent reason men try it first. Cautions: discontinue 2 weeks before surgery (theoretical antiplatelet effect from case reports); additive effect with anticoagulants in some reports. Pregnancy / lactation use is not relevant for BPH but the extract is contraindicated in pregnancy due to anti-androgenic activity.
Stinging nettle root is well-tolerated. Mild GI upset is the most common adverse effect. Theoretical lowering of blood glucose (caution in diabetes medication users) and theoretical antihypertensive effect (modest). The above-ground parts (nettle leaf) have somewhat different effects and are used for allergic rhinitis rather than BPH.
Cost
Saw palmetto (standardised lipid extract) runs $0.20–0.60/day. Branded extracts (Permixon) run higher. Stinging nettle root runs $0.20–0.40/day. The fixed-dose combination products run $0.40–0.80/day.
The important baseline
Any new LUTS in a man over 50 warrants a urologist evaluation that includes IPSS scoring, digital rectal exam, urinalysis, and age-appropriate PSA discussion. Phytotherapy is appropriate for confirmed mild-moderate BPH with bothersome symptoms — not for any urinary complaint. Red flags (haematuria, weight loss, bone pain, rapidly progressive symptoms, elevated PSA, suspicious DRE) escalate the workup beyond supplements.
What we'd actually buy
For mild-moderate BPH after a urologist visit: a standardised saw palmetto extract 320 mg/day for 12 weeks, with IPSS reassessment. If response is partial, consider the saw palmetto + nettle combination as the next step. If response is inadequate after 6 months, alpha-blockers and 5-ARIs are the evidence-based escalation.
Sources
- Tacklind J, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;(12):CD001423. PMID: 23235581
- Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005;5(4):1–11. PMID: 16635963
- Lopatkin N, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms — a placebo-controlled, double-blind, multicenter trial. World J Urol. 2005;23(2):139–146. PMID: 15928959
- Debruyne F, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol. 2002;41(5):497–506. PMID: 12074791
- Bombardelli E, Morazzoni P. Urtica dioica L. Fitoterapia. 1997;68(5):387–402. PMID: 9341614
- Sökeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia. BJU Int. 2000;86(4):439–442. PMID: 10971269